Opto Circuits' subsidiary receives CE approval for TAXCOR Plus

Opto Circuits (India) Ltd.’s wholly-owned subsidiary Eurocor GmbH has received CE (Communité European) Mark approval for marketing and sale of its novel Drug Eluting Stent-Taxcor Plus in world markets (sans US and Japan). Taxcor Plus is on a Cobalt Chromium platform with Stent struts of 0.0025”, which is one of the thinnest struts available in the industry. The stent is coated with Paclitaxel (1µg/mm2). 

Explaining the distinctive technology of this system, Vinod Ramnani, Chairman & Managing Director, OCI, said, “Taxcor Plus provides unique therapeutic benefits to patients requiring Drug Eluting Stents for Coronary Angioplasty. The thinnest stent struts (low profile) result in superior deliverability to culprit lesions as against the other products available in the market. Taxcor Plus is backed by years of research and has shown excellent clinical results as seen with DIOR (Eurocor’s Drug Eluting Balloon).”

Most Drug Eluting Stents (DES) available in the market have a polymer coating to keep the drug intact on the stent struts. However, in a certain group of patients, polymer coatings on DES result in an inflammatory response and a delay in SAT (sub-acute Thrombosis). Taxcor Plus doesn’t use a polymer.

About Opto Circuits (India) Ltd.
Opto Circuits (India) Ltd. (OCI) (BSE Code: 532391; NSE Symbol: OPTOCIRCUI) is a 100 percent EOU and a leading manufacturer of healthcare equipment in India. The product profile includes digital thermometers, sensors, pulse oximeters, patient monitoring systems, stents, catheters and other innovative products. In 2001, OCI acquired 60 per cent stake in Advanced Micronic Devices (AMDL) to market and distribute its products in India. Mediaid came into existence with the acquisition of the patient monitoring division of Palco Labs, US, in end-2003 and it now directly markets OCI’s products in the US. OCI acquired Eurocor GmbH in 2006. Eurocor manufactures Cardiac Stents of various types, including Drug Eluting Coronary stents. In April 2007, OCI ventured into new product segments - Urology, Gastroenterology, Gynecology and Orthopedics after acquiring Devon Innovations Private Limited (Bangalore) and Ormed Medical Technology Limited (Chennai). OCI completed the acquisition of US based Criticare Systems, Inc. in April 2008. Criticare designs, manufactures, and markets leading edge patient monitoring systems, vital signs monitors and gas benches for a wide range of hospitals and alternate health care environments throughout the world. Visit us at www.optoindia.com; www.eurocor.de